ANZCTR search results

Acute chest pain is one of most common causes for visits to emergency department (ED) throughout the world. It represents around 5% of all ED visits. Current processes to rule-out acute myocardial infarction (AMI) in the ED are inefficient, costly, and place burden on a system that is already under considerable strain from overcrowding and a lack of resources. Strategies that reduce the number of patients presenting to ED with chest pain and strategies to streamline the assessment of the patients who arrive at ED are urgently required. In this study, we will evaluate a strategy to identify patients who do not need extensive investigation (including serial troponin testing) for possible AMI. We seek to rapidly rule-out AMI using the Abbott cTnI-Nx assay. This point of care assay could ultimately be utilised in the pre-hospital environment (including health clinics or in the primary care setting), or in the ED setting. The goal is to realise a safe assessment method that is patient focussed, avoids hospital presentations, provides value based care, minimises patient risk and reduces ED overcrowding. This is an observational study. Patients will be treated as per standard care. For patients who consent to participate, an additional sample of blood will be taken at the same time as bloods are taken for standard care. This blood will be frozen and stored in the Emergency Department. This blood will later be thawed and analysed using the new Abbott cTnI-Nx assay. The accuracy of this assay for the diagnosis of AMI will be assessed.

Exploratory trial of The Resilience Project (http://theresilienceproject.com.au) which develops and delivers emotionally engaging programs to schools, sports clubs and businesses, and provides them with evidence-based, practical strategies to build resilience. This study is an evaluation of the Resilience Project in the primary school context. We will examine immediate and maintained changes in behaviour of grade 4 to 6 primary school children in relation to use of gratitude, kindness and mindfulness strategies as well as examining changes in children’s personal affect, gratitude, emotional expression and resilience compared to peers who do not receive the Resilience Project Program.

This study aims to assess the feasibility of a low dose, weekly red blood cell (RBC) transfusion for haemoglobin stability in patients with Myelodysplastic syndromes (MDS). Who is it for? You may be eligible for this study if you are an adult with MDS or mixed myeloproliferative/myelodysplastic neoplasm overlap syndrome (MPN/MDS) and who is transfusion dependent (at least two transfusion episodes and at least four units of RBC, in the last 16 weeks) Study details All eligible participants will be randomly allocated to either the usual care Arm A, (continue with their standard treatment) or to the Intervention group, Arm B. The Arm B intervention will involve weekly RBC transfusion using phenotype/genotype matched red blood cells. The number of units per week will be individualised for each patient in the intervention group. All participants involved will experience both treatment arms during the study. Participants will attend weekly transfusions for 6 weeks .The assessment will involve quality of life questionnaires and blood tests. It is possible that maintaining a more stable haemoglobin between transfusions, by transfusing a smaller number of RBCs weekly, may improve quality of life of participants and reduce symptoms. REDDS2 is a collaborative study with the UK National Health Service Blood and Transplant (UK NHSBT) and will inform the design and conduct of a larger trial that will compare red cell transfusion strategies in patients with transfusion-dependent MDS.

This is Part A of a 2-part, Phase 2, Clinical Trial Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of PRAX-944 in Adults with Essential Tremor. Each participant will complete 3 study periods: Screening, Treatment Period (21 or 28 days) and Safety Follow-up.

The purpose of this study is to test if a chemical called prochlorperazine (Stemetil) can move the target of a chemotherapy drug called cetuximab to the surface of cancer cells. Who is it for? You may be eligible for this study of you are aged 18 or over and have a squamous cell carcinoma of head and neck which is amenable to biopsy Study details All participants in this study will have a small biopsy of their tumour then an infusion of the study drug (prochlorperazine) through a needle in their arm 60-90 minutes before another biopsy of their tumour. The biopsy sample will be analysed in a laboratory to see the effect of the drug on a receptor on the surface of cancer cells. It is hoped this research will demonstrate that prochlorperazine makes cancer cells more sensitive to the chemotherapy drug cetuximab.

This project seeks to determine the feasibility and effectiveness of timing exercise to control blood glucose levels and reduce cardiovascular risk in people with Type 2 Diabetes. People with Type 2 Diabetes will be randomised to standard care alone or with time of exercise specified to coincide with/avoid blood glucose peak. It is hypothesised that individually prescribing ‘the time’ a person should exercise will optimised blood glucose control and attenuate peak blood glucose when compared to standard care and exercise at times other than peak.

Women with Gestational Diabetes (GDM) are recommended to monitor their blood glucose levels (BGLs) aiming at tight control to improve the risk of adverse outcomes. After initial review, our service undertakes weekly phone or email contact with women for surveillance of glycaemia. This creates a significant treatment burden for the patient and clinician. We are investigating the use of the Net-Health mobile phone application (app) and linked glucose meter, as part of a blood glucose management system in women with GDM. This app: 1) Automatically uploads BGLs in real time to a secure server for review remotely by the treating team; 2) Automatically generates an email alert to the treating team if BGLs are out of target range; 3) Allows messaging via the app for dose titration if required. We plan to undertake a pilot study of 100 women, recruited from our GDM group education session. Data will be collected to assess feasibility, patient satisfaction and resource utilisation. We will also gather data to explore patterns of glycaemia, maternal and neonatal outcomes. We hypothesize this management system will be feasible and will lead to a more efficient and responsive model of care and use of resources.

This study aims to evaluate the long term cardiovascular risk factors associated with taking endocrine therapies in patients with oestrogen receptor positive breast cancer. Who is it for? You may be eligible to join this study if you are aged 50-85 years (post-menopausal) and going to commence endocrine therapy treatment for breast cancer for at least 12 months, Study details The study will run for 12 months to observe the potential effects of endocrine treatment on cardiovascular risk factors. The study will involve 3 visits to determine changes in body fat distribution, and other markers of cardiovascular health. Part of the study will involve questionnaires, fasting blood tests, body, liver and bone density scans, There will be an additional blood test done between visits 1 and 3. The results of this study will provide clinicians with a potential means of stratifying each breast cancer woman's cardiovascular risk, enabling delivery of personalised care. This project will also provide a platform for subsequent interventional studies to investigate the clinical impact of risk factor modification.

The study aims to determine whether it is feasible to deliver a particular diet and exercise program for people with hip osteoarthritis who are overweight or obese. We hypothesise that it is feasible to deliver such an intervention.

This study aims to develop a multi-marker assay that will serve as a diagnostic blood test for the detection of early stage melanoma skin cancer (cutaneous melanoma). Who is it for? You may be eligible to join this study if you are aged 18 years or older and have an abnormal skin lesion thought to be melanoma or other types on non-melanoma skin cancer. You must be willing to provide a blood sample prior to your routine skin biopsy. You may additionally be able to participate if you have recently been diagnosed with other types of cancer (early stages) or an autoimmune disease. Study details This study will involve taking a blood sample with a needle from your arm prior to the routine biopsy of your skin lesion. This blood sample will be tested for specific antibodies related to melanoma. The results of this blood test will be compared to results of the biopsy in order to determine how accurate it is at detecting melanoma. It is hoped that this blood test can be used to provide greater diagnostic certainty prior to biopsy and for routine screening of people who are at a higher risk of melanoma.